Paper

2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone.

Published Jul 19, 1999 · DOI · I. Parveen, D. Naughton, W. Whish

Bioorganic & medicinal chemistry letters

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

The 2-nitroimidazol-5-ylmethyl unit shows potential for selective drug delivery to hypoxic tissues through bioreductive activation of the PARP inhibitor 5-bromoisoquinolinone.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone.

References

Citations